Anesthetic Effect - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 56 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Anesthetic Effect - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Anesthetic Effect - Pipeline Review, H2 2014', provides an overview of the Anesthetic Effect's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anesthetic Effect and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anesthetic Effect pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anesthetic Effect Overview 7
Therapeutics Development 8
Pipeline Products for Anesthetic Effect - Overview 8
Pipeline Products for Anesthetic Effect - Comparative Analysis 9
Anesthetic Effect - Therapeutics under Development by Companies 10
Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 12
Anesthetic Effect - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Anesthetic Effect - Products under Development by Companies 17
Anesthetic Effect - Products under Investigation by Universities/Institutes 18
Anesthetic Effect - Companies Involved in Therapeutics Development 19
Advicenne Pharma 19
Lipicard Technologies Limited 20
Maruishi Pharmaceutical Co., Ltd. 21
Merck & Co., Inc. 22
Phosphagenics Limited 23
Physica Pharma 24
Sage Therapeutics 25
Sphaera Pharma Pvt. Ltd. 26
Anesthetic Effect - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 36
(tetracaine + oxymetazoline hydrochloride) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ADV-6209 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LT-1121 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LT-1123 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
methoxycarbonyl carboetomidate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MR-04A3 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PHY-301 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
propofol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SAGE-689 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules for Anesthesia - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sugammadex sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Anesthetic Effect - Recent Pipeline Updates 49
Anesthetic Effect - Dormant Projects 50
Anesthetic Effect - Discontinued Products 51
Anesthetic Effect - Product Development Milestones 52
Featured News & Press Releases 52
Jul 23, 2009: Mass. General Announces Development Of Potentially Safer General Anesthetic, MOC-etomidate 52
Mar 03, 2004: Astrazeneca's Naropin Approved In Europe 52
Jan 19, 2001: Astrazeneca Sells Dental Local Anaesthetic Business To Dentsply International Inc. 53
Dec 20, 2000: AstraZeneca Submits sNDA for Naropin For Use In Pediatric Patients 53
Nov 06, 2000: Astrazeneca Receives US FDA Approval For 72-hour Infusion Of Naropin For Post-operative Pain Management 53
Oct 01, 1996: Astrazeneca Received Regulatory Authorization For Marketing Naropin 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Anesthetic Effect, H2 2014 8
Number of Products under Development for Anesthetic Effect - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Anesthetic Effect - Pipeline by Advicenne Pharma, H2 2014 19
Anesthetic Effect - Pipeline by Lipicard Technologies Limited, H2 2014 20
Anesthetic Effect - Pipeline by Maruishi Pharmaceutical Co., Ltd., H2 2014 21
Anesthetic Effect - Pipeline by Merck & Co., Inc., H2 2014 22
Anesthetic Effect - Pipeline by Phosphagenics Limited, H2 2014 23
Anesthetic Effect - Pipeline by Physica Pharma, H2 2014 24
Anesthetic Effect - Pipeline by Sage Therapeutics, H2 2014 25
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 35
Anesthetic Effect Therapeutics - Recent Pipeline Updates, H2 2014 49
Anesthetic Effect - Dormant Projects, H2 2014 50
Anesthetic Effect - Discontinued Products, H2 2014 51